Tristel Plc

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00B07RVT99
GBP
3.80
0.2 (5.56%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Company has a low Debt to Equity ratio (avg) at times

 
2

Healthy long term growth as Net Sales has grown by an annual rate of 7.95%

 
3

With a growth in Net Sales of 7.36%, the company declared Outstanding results in Jun 25

4

With ROE of 24.75%, it has a fair valuation with a 5.69 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 182 Million (Small Cap)

stock-summary
P/E

23.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

516.38%

stock-summary
Debt Equity

-0.36

stock-summary
Return on Equity

24.75%

stock-summary
Price to Book

5.43

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.15%
0%
15.15%
6 Months
-0.65%
0%
-0.65%
1 Year
-12.64%
0%
-12.64%
2 Years
-12.14%
0%
-12.14%
3 Years
4.11%
0%
4.11%
4 Years
-37.19%
0%
-37.19%
5 Years
-18.28%
0%
-18.28%

Tristel Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
7.95%
EBIT Growth (5y)
6.73%
EBIT to Interest (avg)
5.99
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
1.20
Tax Ratio
15.95%
Dividend Payout Ratio
102.01%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
28.29%
ROE (avg)
16.89%

Valuation key factors

Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
5.69
EV to EBIT
17.57
EV to EBITDA
13.63
EV to Capital Employed
8.37
EV to Sales
3.61
PEG Ratio
1.13
Dividend Yield
351.62%
ROCE (Latest)
47.63%
ROE (Latest)
24.75%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Tristel Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is 10.98% vs 16.39% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is 1.54% vs 44.44% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "46.50",
          "val2": "41.90",
          "chgp": "10.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.80",
          "val2": "10.00",
          "chgp": "28.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.20",
          "chgp": "50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.40",
          "val2": "-0.10",
          "chgp": "-1,300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6.60",
          "val2": "6.50",
          "chgp": "1.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "214.60%",
          "val2": "173.90%",
          "chgp": "4.07%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Jun'25stock-summary

Jun'25
Jun'24
Change(%)
Net Sales
46.50
41.90
10.98%
Operating Profit (PBDIT) excl Other Income
12.80
10.00
28.00%
Interest
0.30
0.20
50.00%
Exceptional Items
-1.40
-0.10
-1,300.00%
Consolidate Net Profit
6.60
6.50
1.54%
Operating Profit Margin (Excl OI)
214.60%
173.90%
4.07%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2025 is 10.98% vs 16.39% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2025 is 1.54% vs 44.44% in Jun 2024

stock-summaryCompany CV
About Tristel Plc stock-summary
stock-summary
Tristel Plc
Pharmaceuticals & Biotechnology
Tristel Plc is a United Kingdom-based manufacturer of infection prevention and contamination control products. The Company's technology is a chlorine dioxide formulation. The Company operates through three segments: Human Healthcare, Animal Healthcare and Contamination Control. The Human Healthcare segment is engaged in the manufacture, development and sale of infection control and hygiene products, which include products that are used primarily for infection control in hospitals. The segments products are marketed under the brand, Tristel. The Animal Healthcare segment relates to manufacture and sale of disinfection and cleaning products into veterinary and animal welfare sectors. The segments products are marketed under the brand, Anistel. The Contamination Control segment addresses the pharmaceutical and personal care product manufacturing industries. The segments products are marketed under the brand, Crystel. Its manufacturing facility is located in Newmarket, Cambridgeshire.
Company Coordinates stock-summary
Company Details
Lynx Business Park,Fordham Road , SNAILWELL None : CB8 7NY
stock-summary
Tel: 44 1638 72150044 1638 721500
stock-summary
Registrar Details